Skip to main content
Premium Trial:

Request an Annual Quote

Bush s 06 NIH Budget Boon for Some Genomic Shops, Hindrance for Others

NEW YORK, Feb. 8 (GenomeWeb News) - President Bush's proposed 2006 NIH budget increase of .7 percent may spur investment in genomics consumables shops such as Cepheid, Illumina, Invitrogen, and Serologicals, but tool makers such as Applied Biosystems are expected to have "ongoing difficulties," according to a Pacific Growth Equities analyst report released today.

 

The "tepid" budget increase, which Pac Growth quipped is "better than a sharp stick in the eye," spurred the equity research firm to reaffirm its investment position as favorable towards companies "that address downstream development functions, particularly those companies whose product mix skews towards consumables and whose technologies may be leveraged in applied markets."

 

Pac Growth said that the increase, which if approved would give the NIH a $28.8 billion budget for fiscal year 2006, was in line with its .5-percent estimate. It also said that investors would "view this modest increase ... as a positive for the life sciences sector."

 

ABI did not immediately return a telephone call seeking comment.

 

In a separate statement, the Federation of American Societies for Experimental Biology expressed disappointment in the budget increase, saying in a statement yesterday that the increase was "well below the rate of inflation," and that it was "concerned that the agency will be unable to sustain its current research program.

 

"The doubling of the NIH budget resulted in a massive amount of new information being generated in every field of biomedical science," FASEB said in its statement. "However, the constrained budget over the past few years has limited NIH's ability to build on these scientific discoveries."

 

FASEB also welcomed the President's proposed 2.4-percent budget increase for the National Science Foundation, but noted that it would still leave the NSF below its 2004 funding level. According to FASEB, the budget proposal includes a .9-percent increase for the biological directorate.

 

The NSF received $5.65 billion in funding in 2004; approximately $5.5 billion last year; and is slated to receive about $5.6 billion in funding in 2006, FASEB said. The US government's fiscal year starts on Oct. 1.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.